Human cytomegalovirus: Challenges opportunities and new drug development

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 5, 1999, Pages 219-232

  Field, A Kirk ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antiviral chemotherapy; HCMV

Indexed keywords

ANTIRETROVIRUS AGENT; BENZIMIDAZOLE; CIDOFOVIR; CYCLOPROPANE DERIVATIVE; FOMIVIRSEN; FOSCARNET; FOSCARNET SODIUM; GANCICLOVIR; GENE EXPRESSION MODULATOR 132; LOBUCAVIR; NEW DRUG; PROTEINASE INHIBITOR; PYRROLOPYRIMIDINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROSCLEROSIS; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; INFLAMMATION; METABOLIC DISORDER; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0032840668     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000501     Document Type: Review

References (113)

1. Arvin AM & Alford CA. (1990) Chronic intrauterine and perinatal infections. In Antiviral Agents and Viral Diseases of Man, pp. 497-580, 3rd Edition. Edited by GJ Galasso, RJ Whitley and TC Merigan. New York: Raven Press.
2. Azad RF, Driver VB, Tanaka K, Crooke RM & Anderson KP (1993) Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrobial Agents and Chemotherapy 37:1945-1954.
3. Azad RF, Brown-Driver V, Buckheit RW Jr & Anderson KP (1995) Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Research 28:101-111.
4. Baldanti F, Underwoood MR, Talarico CL, Simoncini L, Sarasini A, Biron KK & Gerna G (1998) The cys607→tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocom-promised patients. Antimicrobial Agents and Chemotherapy 42:444-446.
5. Baum EZ, Bebernitz GZ & Hulmes JD (1993) Expression and analysis of the human cytomegalcvirus UL 80-encoded protease: identification of autoproteolytic sites. Journal of Virology 67:497-506.
6. Bedard J, May S, Lis M, Tryphonas L, Drach J, Huffman J, Sidwell R, Chan L, Bowlin T & Rando R (1999) Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Antimicrobial Agents and Chemotherapy 43:557-567.
7. Bidanset-Ponder D & Kern ER (1999) Animal models for ocular cytomegalovirus infections in SCID-hu mice. In Handbook on Animal Models for Antimicrobial Therapy. Edited by O Zak, M Sande, C Carbon, R Kaninsky, T O'Reilly & E Kern. New York: Academic Press (in press).
8. Bidanset DJ, Rybak RJ, Hartline CB & Kern ER (1998) Inhibition of human cytomegalovirus replication in SCID-hu retinal tissue implants by ganciclovir and cidofovir. Antiviral Research 37:A69, Abstract 107.
9. Bidanset DJ, Rybak RJ, Hartline CB & Kern ER (1999) Use of the SCID-hu retinal implant model for determining the efficacy of antiviral therapies against human cytomegalovirus infections. Antiviral Research 41:A64, Abstract 103.
10. Borthwick AD, Weingarten G, Haley TM, Tomaszewski M, Wang W, Hu Z, Bedard J, Jin H, Yuen L & Mansour TS (1998) Design and synthesis of nonocyclic beta-lactams as mechanism-based inhibitors of human cytomegalovirus protease. Bioorganic & Medicinal Chemistry Letters 17:365-370.
11. Borthwick AD, Crame A, Exall AM, Jackson DL, Mason AM, Pennell AMK, Weingarten GG, Haley TM, Hart GJ & Parry NR (1999) Pyrrolidine-5,5-translactams, novel herpes protease inhibitors that are potent antiviral against human cytomegalovirus. Antiviral Research 41:A35, Abstract 14.
12. Braitman A, Swerdel MR, Olsen SJ, Tuomari AV, Lynch JS, Blue B, Michalik T, Field AK, Bonner DP & Clark JM (1991) Evaluation SQ 43,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice. Antimicrobial Agents and Chemotherapy 35:1464-1468.
13. Brown JM, Kaneshima H & Mocarski ES (1995) Dramatic interstrain differences in the replication of human cytomegalovirus in SCID-hu mice. Journal of Infectious Diseases 171:1599-1603.
14. Burd EM, Pulido JS, Puro DG & O'Brien WJ (1996) Maintenance of replicative intermediates in ganciclovir-treated human cytomegalovirus-infected retinal glia. Archives of Ophthalmology 114:856-861.
15. Casado JL, Perez-Elias MJ, Marti-Belda P, Antela A, Suarez M, Ciancas E, Frutos B, Perez MD & Guerrero A (1998) Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 19:130-134.
16. Cherrington JM, Fuller MD, Lamy PD, Miner R, Lalezari JP, Nuessle S & Drew WL (1998) In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. Journal of Infectious Diseases 187:1821-1825.
17. Chou S, Guentzel S, Michels KR, Miner RC & Drew WL (1995) Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. Journal of Infectious Diseases 172:239-242.
18. Chou S, Marousek G, Grentzel S, Follansbee SE, Poscher ME, Lalezari JP, Miner RC & Drew WL (1997) Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. Journal of Infectious Diseases 176:786-789.
19. Chou S, Marousek G, Parenti DM, Gordon SM, LaVoy AG, Ross JG, Miner RC & Drew WL (1998) Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. Journal of Infectious Diseases 178:526-530.
20. Chrisp PL & Clissold SP (1991) Foscarnet. Drugs 41:104-129.
21. Chulay J, Biron K, Wang L, Koszalka G, Underwood M, Chamberlain S, Frick L, Good S, Davis M, Harvey R, Townsend L & Drach J (1999) Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. In Antiviral Chemotherapy 5 : New Directions for Clinical Application and Research (Advances in Experimental Medicine and Biology, volume. 458). Edited by J Mill, P Volberding & L Corey. Plenum Publishing Corporation: New York.
22. Cihlar T & Hitchcock MJM (1998) Human cytomegalovirus DNA polymerase and antiviral drug resistance: recent progress. International Antiviral News 6:162-166.
23. Cihlar T, Fuller MD & Cherrington JM (1998a) Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. Journal of Virology 72:5927-5936.
24. Cihlar T, Fuller MD, Mulato AS & Cherrington JM (1998b) A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell cutlure. Virology 248:382-393.
25. Couchoud C, Cucherat M, Haugh M & Pouteil-Noble C (1998) Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 65:641-647.
26. de Jong MD, Galasso GJ, Gazzard B, Griffiths PD, Jabs DA, Kern ER & Spector SA (1998) Summary of the II International Symposium on cytomegalovirus. Antiviral Research 39:141-162.
27. o with monocyclic Beta-lactams. Antiviral Research 37:A68, Abstract 102.
28. DiLorato D, Epstein LG, Lazar ES, Britt WJ & del Cerro M (1994) Cytomegalovirus infection of human retinal tissue: an in vivo model. Laboratory Investigations 71:141-148.
29. Drew WL (1991) Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance. Journal of Acquired Immune Deficiency Syndromes 4:S42-S46.
30. Drew WL, Miner RC, Busch DF, Follanbee SE, Gullett J, Mahalko SG, Gordon SM, Owen WF, Matthews TR, Buhles WC & DeArmond B (1991) Prevalence of CMV resistance in patients receiving ganciclovir for serious CMV infection. Journal of Infectious Diseases 163:716-719.
31. Egan JJ, Lomax J, Barber L, Lok SS, Martyszczuk R, Yonan N, Fox A, Deiraniya AK, Turner AJ & Woodcock AA (1998) Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 15:747-752.
32. Eizuru Y (1998) Multidrug resistance in human cytomegalovirus. International Antiviral News 6:61-63.
33. Erice A, Gil-Roda C, Perez JL, Balfour HH, Sannerud KJ, Hanson MN, Boivin G & Chou S (1997) Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. Journal of Infectious Diseases 175:1087-1092.
34. Erice A, Borrell N, Li W, Miller WJ & Balfour HH (1998) Ganciclovir susceptibilities and analysis of UL97 region in cytomegaloivrus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. Journal of Infectious Diseases 178:531-534.
35. Fabricant CG (1986) Viruses: causal factors in atherosclerosis. Microbiological Science 3:50-52.
36. Falagas ME, Paya C, Ruthazer R, Badley A, Patel R, Wiesner R, Griffith J, Freeman R, Rohrer R, Werner BG & Snydman DR (1998) Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 66: 1020-1028.
37. Field AK (1998) Viral targets for antisense oligonucleotides: a mini review. Antiviral Research 37:67-81.
38. Field AK & Biron KK (1994) "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs. Clinical Microbiology Reviews 7:1-13.
39. Field AK, Tuomari AV, McGeever-Rubin B, Terry BJ, Mazina KE, Haffey ML, Hagen ME, Clark JM, Braitman A, Slusarchyk WA, Young MG & Zahler R (1990) (+/-)-(1alpha, 2beta, 3alpha)-9-[2,3-bis(hydroxymethyl)-cyclovutyl]guanine [(+/-)-BHCG or SQ 33054]: a potent and selective inhibitor of herpesviruses. Antiviral Research 13:41-52.
40. Field AK, Pari GS & Martin RR (1997) GEM 132- an antisense drug for the treatment of CMV. International Antiviral News 5:219-222.
41. Flores-Aguilar M, Besen G, Vuong C, Tatebayashi M, Munguia D, Gangan P, Wiley CA, Freeman WR (1997) Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. Journal of Infectious Diseases 175:1308-1316.
42. Gerna G, Zipeto D & Percivalle E (1992) Human cytomegalovirus infection of the major leukocyte subpopulations and evidence from initial viral replication in polymorphonuclear leukocytes from viremic patients. Journal of Infectious Diseases 166:1236-1244.
43. Gibson W (1991) Cytomegalovirus protein structure and function. In Progress in Cytomegalovirus Research, pp. 357-370. Edited by MP Landini. Amsterdam: Elsevier.
44. Haffey ML & Field AK (1995) Selective inhibition of cytomegalovirus replication. In Antiviral Chemotherapy, pp. 83-126. Edited by DJ Jeffries and E DeClercq. New York: John Wiley & Sons.
45. Hajjar DP, Fabricant CG, Minick CR, Fabricant J (1986) Virus-induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation. American Journal of Pathology 122:62-70.
46. Hartline CB, Zemlicka J, Qiu Y-L, Bidanset DJ, Harden E, Sommadossi J-P & Kern ER (1998) In vitro activity of methyl-enecyclopropane analogues of nucleosides against cytomegalovirus infections. Antiviral Research 37:A82, Abstract 149.
47. Hayashi S, Norbeck DW, Rosenbrook W, Fine RL, Matsukura M Plattner JJ, Broder S & Mitsuya (1990) Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro. Antimicrobial Agents and Chemotherapy 34:287-294.
48. Hitchcock MJM, Jaffe HS, Martin JC & Stagg RJ (1996) Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chemistry & Chemotherapy 7:115-127.
49. Ho H-T, Woods KL, Bronson JJ, De Boeck H, Martin JC & Hitchcock MJ (1992) Intracellular metabolism of the antiherpes agent (S)-1[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine on lymphocyte transformation and delayed-type hypersensitivity responses. Molecular Pharmacology 41:197-202.
50. Houhou-Fidouh N, Mazeron MC, Dewilde A, Thouvenot D, Scieux C, Aissa N, Carquin J & Freymuth F (1998) Comparison of the in vitro sensitivity to cidofovir and ganciclovir of clinical cytomegalovirus isolates. Coordinated action group 11. Pathologique Biologie (Paris) 46:420-422.
51. Jabs DA (1995) Ocular manifestations of HIV infection. Transactions of the American Ophthalmological Society 93:623-683.
52. Jabs DA, Enger C, Dunn JP & Forman M (1998a) Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV retinitis and viral resistance study group. Journal of Infectious Diseases 177:770-773.
53. Jabs DA, Enger C, Forman M & Dunn JP for the cytomegalovirus retinitis and viral resistance study group (1998b) Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrobial Agents and Chemotherapy 42:2240-2244.
54. Jacobson JG, Renau TE, Nassiri MR, Sweier DB, Breitenbach JM, Townsend LB & Drach JC (1999a) Non-nucleoside pyrrolopyrimidines with a unique mechanism of faction against human cytomegalovirus. Antiviral Research 41:A35, Abstract 15.
55. Jacobson JG, Renau TE, Nassiri MR, Sweier D, Breitenbach JM, Townsend LB & Drach JC (1999b) Non-nucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus. Antimicrobial Agents and Chemotherapy 43:1888-1894.
56. 1-PDX: a potent new anti-cytomegalovirus drug. Antiviral Research 37: A69, Abstract 104.
57. Jones TR, Sun L & Bebernitz GA (1994) Proteolytic activity of human cytomegalovirus UL 80 protease cleavage site mutants. Journal of Virology 68:3742-3752.
58. Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA & McCune JM (1998) Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nature Medicine 4:953-956.
59. Krosky PM, Underwood MR, Turk SR, Feng KW-H, Jain RK, Ptak RG, Westerman AC, Biron KK, Townsend LB & Drach JC (1998) Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. Journal of Virology 72:4721-4728.
60. Kuppermann BD (1997) Therapeutic options for resistant cytomegalovirus retinitis. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14:S13-S21.
61. Lagace L, Do F, Malenfant E, Deziel R & Cordingley MG (1998) Inhibition of proteinase dependent processing of the scaffold proteins of HCMV capsid by monocyclic Beta-lactams. Antiviral Research 37:A84, Abstract 158.
62. Laycock KA, Fenoglio ED, Hook KK & Pepose JS (1997) An in vivo model of human cytomegalovirus retinal infection. American Journal of Ophthalmology 124:181-189.
63. Laycock KA, Kumano Y & Pepose JS (1998) Reproduction of antiviral effect in an in vivo model of human cytomegalovirus retinal. Infection Graefes Archives of Clinical and Experimental Ophthalmology 236:527-530.
64. Leeds JM, Henry SP, Truong L, Zulshi A, Levin AA & Kornbrust D (1997) Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metabolism and Disposition 25:921-926.
65. Leeds JM, Henry SP, Bisrner S, Scherrill S, Williams K & Levin AA (1998) Pharmacokinetics of an antisense oligonucleotide injected intreavitreally in monkeys. Drug Metabolism and Disposition 26:670-675.
66. Lipson SM, Match ME, Toro AI, Kaplan MH & Shepp DH (1998) Application of a standardized cytomegalovirus antigenemia assay in the management of patients with AIDS. Diagnostic Microbiology Infectious Disease 32:75-79.
67. Littler E, Stuart AD & Chee MS (1992) Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analog ganciclovir. Nature 358:160-162.
68. Liu W, Kuppermann BD, Martin DF, Wolitz RA & Margolis TP (1998) Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis. Journal of Infectious Diseases 177:1176-1181.
69. McSharry JJ, Lurain NS, Drusano GL, Landay A, Manischewitz J, Nokta M, O'Gorman M, Shapiro HM, Weinberg A, Reichelderfer P & Crumpacker C (1998a) Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. Journal of Clinical Microbiology 36:958-964.
70. McSharry JJ, Lurain NS, Drusano GL, Landay AL, Notka M, O'Gorman MR, Weinberg A, Shapiro HM, Reichelderfer PS & Crumpacker CS (1998b) Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates. Antimicrobial Agents and Chemotherapy 42:2326-2331.
71. McSharry JJ, Lurain NS, Davis M, Talarico CL, Biron KK & Crumpacker CS (1999) Comparison of the in vitro antiviral activities of 1263W94, ganciclovir, foscarnet and cidofovir for human cytomegalovirus (HCMV) clinical isolates as determeind by flow cytometry and plaque reduction assays. Antiviral Research 41:A62, Abstract 95.
72. Manteiga R, Martino R, Sureda A, Labeaga R, Brunet S, Sierra J & Rabella N (1998) Cytomegalovirus pp65 antigenemia-guided preemptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Bone Marrow Transplant 22:899-904.
73. Melnick JL, Hu C, Adams E & DeBakey ME (1994) Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. Journal of Medical Virology 42:170-174
74. Mocarski ES, Bonyhadi M, Salimi S, McCure JM & Kaneshima H (1993) Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominant targets of viral replication. Proceedings of the National Academy of Sciences, USA 90:104-108
75. Moretti S, Zikos P, Ban Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B & Bacigalupo A (1998) Foscarnet vs ganciclovir afor cytomegaolvirus (CMV) antigenemia after allogeneic hempoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 22:175-180.
76. Mousavi-Jazi M, Brytting M & Sundqvist V-A (1998) A point mutation within the CMV DNA polymerase confers cross-resistance to foscarnet and ganciclovir. Antiviral Research 37:A85, Abstract 163.
77. Mulamba GB, Hu A, Azad RF, Anderson KP & Coen DM (1998) Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrobial Agents and Chemotherapy 42:971-973.
78. Nassiri MR, Emerson SG, Devirar RV, Townsend LB, Drach JC & Taichman RS (1996) Comparison of benzimidazole nucleosides and ganciclovir on the in vitro proliferation and colony formation of human bone marrow progenitor cells. British Journal of Haematology 93:273-279.
79. Pari GS, Field AK & Smith JA (1995) Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37. Antimicrobial Agents and Chemotherapy 39:1157-1161.
80. Pari GS, Netski D, St Jeor S, McCarthy D, Smith J, Georgio D & von Hofe E (1998) Generation of a nude mouse tumor model for in vivo replication of human cytomegalovirus. Journal of Infectious Diseases 177:523-528.
81. Paul S & Drummer S (1992) Topics in clinical pharmacology: ganciclovir. American Journal of Medical Science 304:272-277.
82. Perez JE (1997) Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance. Microbiologia 13:343-352.
83. Pillay D, Emery VC & Griffiths PD (1995) Clinical aspects of treatment of cytomegalovirus. In Clinical Aspects of Treatment of Cytomegalovirus, pp. 265-283. Edited by DJ Jeffries & E DeClercq. New York: John Wiley & Sons.
84. Prix E, Maierl J, Jahn G & Hamprecht K (1998) A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains. Journal of Clinical Virology 24:29-37.
85. Qian-Cutrone J, Kolb JM, McBrien K, Huang S, Gustavson D, Lowe SE & Manly SP (1998) Quanolirones I and II, two new human cytomegalovirus protease inhbitiors produced by streptomyces sp. WC76535. Journal of Natural Products 61:1379-1382.
86. Renau TE, Eudwig MS, Drach JC & Townsend LB (1992) Design, synthesis and activity against human cytomegalovirus of non-phosphorylatable analogs of toyocamycin, sangivamycin, and thiosangivamycin. Bioorganic & Medicinal Chemistry Letters 2:1755-1760.
87. Rybak RJ, Zemlicka J, Qiu Y-L, Kern ER (1998) Effective treatment of murine cytomegalovirus infections with methylenecyclopropane analogues of nucleosides. Antiviral Research 37:A82, Abstract 150.
88. Schaarschmidt MD, Wunderlich K, Heuschmid M, Simoncini L, Muhlberger D, Zimmermann A, Pavic I & Mertens T (1998) Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. Journal of General Virology 79:2105-2112.
89. Seifer M, Hamatake RK, Colonno RJ & Standring DN (1998) In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrobial Agents and Chemotherapy 42:3200-3208.
90. Shieh H, Stallings W, Wittwer A, Hippenmeyer P, Kurumbail R & Holwerda B (1997) Crystal structures of human cytomegalovirus protease delineate a new target for antiherpes drug design. International Antiviral News 5:71-73.
91. Shu YZ, Ye Q, Kolab JM, Huang S, Veitch JA, Lowe SE & Manly SP (1997) Bripiodionen, an new inhibitor of human cytomegalovirus protease from Streptomyces sp. WC76599. Journal of Natural Products 60:529-532.
92. Singer C & Jahn G (1996) Human cytomegalovirus cell tropism and pathogenesis. Intervirology 39:302-319.
93. Smith JA & Pari GS (1995) Expression of human cytomegalovirus UL36 and UL 37 genes is required for viral DNA replication. Journal of Virology 69:1925-1931.
94. Smith IL, Shinkai M, Freeman WR & Spector SA (1996) Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. Journal of Infectious Diseases 173:1481-1484.
95. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR & Spector SA (1997) High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. Journal of Infectious Diseases 176:69-77.
96. Smith IL, Taskintuna I, Rahhal FM, Powell HC, Ai E, Mueller AF, Spector SA & Freeman WR (1998) Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Archives of Ophthalmology 116:178-185.
97. Snoeck R, Sakuma T & De Clercq E (1988) (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy 32:1839-1844.
98. Speir E, Modali R, Huang E-S, Leon MB, Shawl F, Finkel T & Epstein SE (1994) Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394.
99. Stals FS, De Clercq E & Bruggeman CA (1991) Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine [DHPG] against rat cytomegalovirus infection in vitro and in vivo. Antimicrobial Agents and Chemotherapy 35:2262-2266.
100. Stanat SC, Reardon JE, Erice A & Biron KK (1991) Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrobial Agents and Chemotherapy 35:2191-2197.
101. Sullivan V, Talarico CL, Stanat SC, Biron KK (1992) A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegaloivirus-infected cells. Nature 358:162-164.
102. Tenney DJ, Yamanaka G, Voss SM, Cianci CW, Tuomari AV, Sheaffer AK, Alam M & Colonno RJ (1997) Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase. Antimicrobial Agents and Chemotherapy 41:2680-2685.
103. Terry BJ, Mazina KE, Tuomari AV, Hagen ME, Haffey ML, Jacobs GA, Zahler R & Field AK (1990) Anti-herpetic activity of (+/-)-(1alpha, 2beta, 3alpha)-9-[2-hydroxy-3-(hydroxymethyl) cyclobutyl]guanine and inhbition of HSV-1 DNA polymerase. Antiviral Chemistry & Chemotherapy 1:263-268.
104. Townsend LB, Devivar RV, Turk SR, Nassiri MR & Drach JC (1995) Design, synthesis, and antiviral activity of certain 2,5,6-tri-halo-1-(beta-D-ribofuranosyl)benzimidazoles. Journal of Medicinal Chemistry 38:4098-4105.
105. Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB & Biron KK (1998) Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. Journal of Virology 72:717-725.
106. Watanabe S, Konno K, Shigeta S & Yokota T (1998) Inhibition of human cytomegalovirus proteinase by salcomine derivatives. Antiviral Research 37:A83, Abstract 155.
107. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA & Kessler HA (1998) Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Archives of Internal Medicine 58:957-969.
108. Wolf DG, Honigman A, Lazarovits J, Tavor E & Panet A (1998a) Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase. Archives of Virology 143:1223-1232.
109. Wolf DG, Yaniv I, Honigman A, Kassis I, Schonfeld T & Ashkenazi S (1998b) Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. Journal of Infectious Diseases 178:535-538.
110. Yamanaka G, Tuomari AV, Hagen M, McGeever-Rubin B, Terry B, Haffey M, Bisacchi GS & Field AK (1991) Selective activity and cellular pharmacology of (1R-1alpha, 2beta, 3alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine in herpesvirus-infected cells. Molecular Pharmacology 40:446-453.
111. Yang CW, Kim YO, Kim YS, Kim SY, Moon IS, Ahn HJ, Koh YB & Bang BK (1998) Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. American Journal of Nephrology 18:373-378.
112. Zacny VL, Davis MG, Biron KK & Pagano JS (1997) Activity of benzimidazole riboside 1263W94 (5,6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole against Epstein-Barr virus. Antiviral Research 34:A85, Abstract 156.
113. Zhu H, Cong JP, Mamtora G, Gingeras T & Shenk T (1998) Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proceedings of the National Academy of Sciences, USA 95:14470-14475.